19-383 - A Study for Participants Who Were Treated for Relapsing Forms of Multiple Sclerosis (RMS)Status: open
Cladribine tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Participants Previously Treated for Relapsing Forms of Multiple Sclerosis (RMS)
Patients with relapsing Multiple Sclerosis (RMS)
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at email@example.com.
The purpose of this study is to evaluate the effectiveness and safety of cladribine tablets in participants with relapsing form of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS) who transition to cladribine tablets after suboptimal response to any oral DMD approved in the United States for RMS in a real-world setting.
SponsorsThis trial is sponsored by Merck.
Providers Associated With This Trial
- William Kilgo, M.D.NeurologistAssistant Professor of Neurology